Orville Kolterman is the Chief Medical Officer at Pendulum. Dr. Kolterman received his BA degree from the University of Kansas followed by a MD degree from Stanford University and postgraduate training in Endocrinology and Metabolism. Following stints on the faculty at the University of Colorado and University of California, San Diego, he embarked upon a parallel career in drug development at Amylin Pharmaceuticals, Inc. Prior to his appointment as Senior Vice President & Chief Medical Officer, Dr. Kolterman held leadership roles in the regulatory, research, development, clinical and medical affairs departments, many of which were officer-level positions. During his 20 year tenure at Amylin, Dr. Kolterman led teams that developed four novel, first in class, drugs currently used by patients with both type 1 and type 2 diabetes. One of the drugs has an orphan indication for the treatment of lipodystrophy. Amylin was acquired by Bristol Myers Squibb in 2012.